Equities Analysts Issue Forecasts for VNDA FY2025 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Vanda Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical company will post earnings per share of $1.30 for the year. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($0.32) per share.

A number of other equities research analysts have also commented on the company. StockNews.com began coverage on Vanda Pharmaceuticals in a research report on Monday. They set a "hold" rating on the stock. HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday.

Vanda Pharmaceuticals Stock Up 1.6 %

Vanda Pharmaceuticals stock traded up $0.07 during mid-day trading on Thursday, hitting $4.42. 491,628 shares of the company's stock were exchanged, compared to its average volume of 612,273. The company's 50 day simple moving average is $4.77 and its 200-day simple moving average is $5.02. The firm has a market capitalization of $257.73 million, a P/E ratio of -15.79 and a beta of 0.77. Vanda Pharmaceuticals has a fifty-two week low of $3.46 and a fifty-two week high of $6.75.

Insider Transactions at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares of the company's stock, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 8.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. ORG Wealth Partners LLC bought a new stake in Vanda Pharmaceuticals in the 3rd quarter valued at $40,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 4,374 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals in the second quarter valued at about $75,000. Intech Investment Management LLC acquired a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $84,000. Finally, SG Americas Securities LLC grew its stake in Vanda Pharmaceuticals by 88.5% in the 3rd quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 9,580 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.